Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Pathogenesis and Treatment of Autoimmune and Inflammatory Rheumatic Diseases
share announcement

Pathogenesis and Treatment of Autoimmune and Inflammatory Rheumatic Diseases

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 1222

Special Issue Editors

Dr. Anna Bazsó

E-Mail
Guest Editor
1. Department of Clinical Immunology, Adult and Paediatric Rheumatology, National Institute of Locomotor System Disorders and Disabilities, Budapest, Hungary
2. Division of Locomotor System and Rheumatology Prevention, Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary
Interests: autoantibodies; rheumatic diseases; autoimmunity; clinical rheumatology; rheumatoid arthritis
Dr. Emese Virág Kiss

E-Mail Website
Guest Editor
1. Department of Clinical Immunology, Adult and Paediatric Rheumatology, National Institute of Locomotor System Disorders and Disabilities, Budapest, Hungary
2. Division of Locomotor System and Rheumatology Prevention, Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary
Interests: rheumatic diseases; autoimmunity; immunology; clinical trials; inflammation; autoimmune disorders; osteoporosis; inflammatory diseases; innate immunity; cardiac imaging

Special Issue Information

Dear Colleagues,

Rheumatic diseases encompass a diverse range of autoimmune disorders that predominantly impact the joints, bones, muscles, and connective tissues. These chronic conditions, including rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, and ankylosing spondylitis, lead to immune system dysregulation. Various types of rheumatic diseases exhibit a wide spectrum of clinical manifestations and intricate pathogeneses.

The objective of this Special Issue is to encourage researchers to disseminate their latest research findings and provide a comprehensive overview of recent advancements in the clinical and pathological aspects of rheumatic diseases. We cordially invite investigators to contribute their original research and review articles focusing on the pathogenesis and therapeutics of autoimmune and inflammatory Rheumatic Diseases.

Dr. Anna Bazsó
Dr. Emese Virág Kiss
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 4150 KiB  
Article
Antiphospholipid Antibodies Are Major Risk Factors for Non-Thrombotic Cardiac Complications in Systemic Lupus Erythematosus
by Nikolett Nagy, Bernadett Bói, Gábor Papp, Edit Fiák, Eszter Gáspár-Kiss, Bianka Perge, Nikolett Farmasi and Tünde Tarr
Biomedicines 2024, 12(3), 530; https://doi.org/10.3390/biomedicines12030530 - 27 Feb 2024
Viewed by 1069
Abstract
In systemic lupus erythematosus (SLE), cardiovascular complications are among the leading causes of death. Cardiovascular risk in SLE is even higher in the presence of antiphospholipid antibodies or secondary antiphospholipid syndrome (APS). The aim of this retrospective, single-center study was to investigate the [...] Read more.
In systemic lupus erythematosus (SLE), cardiovascular complications are among the leading causes of death. Cardiovascular risk in SLE is even higher in the presence of antiphospholipid antibodies or secondary antiphospholipid syndrome (APS). The aim of this retrospective, single-center study was to investigate the occurrence of antiphospholipid antibodies and non-thrombotic cardiac manifestations in 369 SLE patients. We also assessed the clinical and laboratory characteristics of the patients to reveal the risk factors for cardiac manifestations. Patients were divided into two groups based on the presence of antiphospholipid antibodies (APA); 258 (69.9%) patients were APA positive, and 111 (30.1%) patients were APA negative. Mitral and tricuspid insufficiency, aortic stenosis and pulmonary arterial hypertension were more common in APA-positive patients. Anticardiolipin IgG showed the strongest correlation with any non-thrombotic cardiac manifestations. Based on our results, the adjusted global antiphospholipid syndrome score (aGAPSS) above 8.5 is predictive of valvulopathies and ischemic heart disease, while aGAPSS above 9.5 is predictive of cardiomyopathies. The presence of antiphospholipid antibodies may affect the development of cardiac manifestations in SLE. Periodic cardiological and echocardiographic screening of patients without cardiac complaints, as well as regular monitoring of antiphospholipid antibodies, have great importance during the treatment of SLE patients. Full article
(This article belongs to the Special Issue Pathogenesis and Treatment of Autoimmune and Inflammatory Rheumatic Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop